Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Amerigen Pharmaceuticals has entered into a collaboration agreement with Chinese firm Ningbo Menovo Pharmaceutical (Menovo) to develop generic pharmaceuticals, primarily targeting the US market.
Subscribe to our email newsletter
Both the companies will be responsible for jointly developing products which will be commercialized by Amerigen in the US.
As part of the deal, Menovo will oversee manufacturing API and finished product, while Amerigen will be in charge for clinical, regulatory and commercial activities in the US.
The deal will also see Amerigen provide additional support and assistance to Menovo in securing US Food and Drug Administration (FDA) approval for their finished dose manufacturing site in Daxie, China.
Amerigen president and CEO John Lowry said the collaboration allows each party to leverage their respective strengths and will broaden the company’s product pipeline.
"Our first product opportunity leverages formulation work already undertaken by Amerigen at its Suzhou facility and Menovo’s leading position with the corresponding API," Lowry said.
Menovo CEO Adam Yao said, "By partnering with Amerigen, who is an existing supplier of finished product from China into the United States market from their US FDA and CFDA approved facility in Suzhou, we look forward to accelerating our strategic objective of growing our international business in API’s and integrating this into self-manufactured finished product of the highest quality."